PAI-1 and atherothrombosis.
Plasminogen activator inhibitor-1 (PAI-1) is the major physiologic inhibitor of tissue-type plasminogen activator in plasma, and is elevated in a variety of clinical situations that are associated with increased risk of ischemic cardiovascular events. Recent insights into the biology of PAI-1 suggest that it is more than just an innocent bystander in the pathogenesis of ischemic heart disease. Elevated PAI-1 levels appear to increase the risk of atherothrombotic events and may also promote the progression of vascular disease. The development and testing of specific PAI-1 antagonists will enable basic and clinical investigators the opportunity to test the hypothesis that vascular PAI-1 excess promotes the development of intravascular thrombosis and atherosclerosis.
Vaughan
D E
DE
Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-6300, USA. doug.vaughan@vanderbilt.edu
D000818:Animals; D050197:Atherosclerosis / Q000378:metabolism* / Q000473:pathology; D002318:Cardiovascular Diseases / Q000378:metabolism; D002940:Circadian Rhythm; D003924:Diabetes Mellitus, Type 2 / Q000097:blood; D006801:Humans; D007333:Insulin Resistance; D007511:Ischemia; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood* / Q000502:physiology*; D017434:Protein Structure, Tertiary; D013927:Thrombosis / Q000378:metabolism* / Q000473:pathology
D017395:Plasminogen Activator Inhibitor 1